» Articles » PMID: 30686983

Tau and MTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development

Overview
Journal Front Neurosci
Date 2019 Jan 29
PMID 30686983
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

The hyperphosphorylation of tau protein and the overexpression of mTOR are considered to be the driving force behind Aβ plaques and Neurofibrillay Tangles (NFT's), hallmarks of Alzheimer's disease (AD). It is now evident that miscellaneous diseases such as Diabetes, Autoimmune diseases, Cancer, etc. are correlated with AD. Therefore, we reviewed the literature on the causes of AD and investigated the association of tau and mTOR with other diseases. We have discussed the role of insulin deficiency in diabetes, activated microglial cells, and dysfunction of blood-brain barrier (BBB) in Autoimmune diseases, Presenilin 1 in skin cancer, increased reactive species in mitochondrial dysfunction and deregulated Cyclins/CDKs in promoting AD pathogenesis. We have also discussed the possible therapeutics for AD such as GSK3 inactivation therapy, Rechaperoning therapy, Immunotherapy, Hormonal therapy, Metal chelators, Cell cycle therapy, γ-secretase modulators, and Cholinesterase and BACE 1-inhibitors which are thought to serve a major role in combating pathological changes coupled with AD. Recent research about the relationship between mTOR and aging and hepatic Aβ degradation offers possible targets to effectively target AD. Future prospects of AD aims at developing novel drugs and modulators that can potentially improve cell to cell signaling, prevent Aβ plaques formation, promote better release of neurotransmitters and prevent hyperphosphorylation of tau.

Citing Articles

Alzheimer's disease and infectious agents: a comprehensive review of pathogenic mechanisms and microRNA roles.

Hosseininasab S, Ebrahimi R, Yaghoobpoor S, Kazemi K, Khakpour Y, Hajibeygi R Front Neurosci. 2025; 18():1513095.

PMID: 39840010 PMC: 11747386. DOI: 10.3389/fnins.2024.1513095.


Unveiling biomarker detection in Alzheimer's disease: a computational approach to microarray analysis.

Khan N, Choudhary S, Ali M, Shawaz M, Lohnes B, Poddar N 3 Biotech. 2024; 14(12):311.

PMID: 39606011 PMC: 11589038. DOI: 10.1007/s13205-024-04159-4.


Pathway enrichment in genome-wide analysis of longitudinal Alzheimer's disease biomarker endophenotypes.

Rosewood T, Nho K, Risacher S, Liu S, Gao S, Shen L Alzheimers Dement. 2024; 20(12):8639-8650.

PMID: 39440837 PMC: 11667536. DOI: 10.1002/alz.14308.


The multifaceted role of mitochondria in autism spectrum disorder.

Khaliulin I, Hamoudi W, Amal H Mol Psychiatry. 2024; 30(2):629-650.

PMID: 39223276 PMC: 11753362. DOI: 10.1038/s41380-024-02725-z.


Admixture mapping of cognitive function in diverse Hispanic and Latino adults: Results from the Hispanic Community Health Study/Study of Latinos.

Xia R, Jian X, Rodrigue A, Bressler J, Boerwinkle E, Cui B Alzheimers Dement. 2024; 20(9):6070-6081.

PMID: 38946675 PMC: 11497725. DOI: 10.1002/alz.14082.


References
1.
Hardie D, Salt I, Hawley S, DAVIES S . AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J. 1999; 338 ( Pt 3):717-22. PMC: 1220108. View

2.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

3.
Jicha G, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J . cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci. 1999; 19(17):7486-94. PMC: 6782506. View

4.
Ebneth A, Drewes G, Mandelkow E, Mandelkow E . Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of microtubules in cells. Cell Motil Cytoskeleton. 1999; 44(3):209-24. DOI: 10.1002/(SICI)1097-0169(199911)44:3<209::AID-CM6>3.0.CO;2-4. View

5.
Combs C, Johnson D, Karlo J, Cannady S, Landreth G . Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000; 20(2):558-67. PMC: 6772401. View